April 13, 2015
ViiV Healthcare K.K. said on March 10 that it launched on the same day its once-daily, single-tablet HIV treatment Triumeq, a fixed-dose combination tablet containing dolutegravir, abacavir, and lamivudine. The company will copromote the product with Shionogi, while GlaxoSmithKline K.K...read more